Eccogene is a biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. Eccogene is specialized in disease biology, medicinal chemistry, and translational science to advance its novel and differentiated pipeline of drugs to address the unmet medical needs for metabolic and immune-related diseases.
Location: China, Shanghai, Pudong
Employees: 11-50
Total raised: $25.2M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | New Allian... | nac-capita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.06.2023 | Series B | $25.2M | Qingsong F... |
Mentions in press and media 6
| Date | Title | Description |
| 09.11.2023 | Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases | Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments. AstraZeneca will receive an exc... |
| 12.06.2023 | Eccogene Raises CNY 180M in Series B Equity Financing | Eccogene, a Shanghai, China-based clinical-stage biotechnology company, raised CNY180M (approx. $25M) in Series B Equity funding. The round by co-led by New Alliance Capital and Zhangjiang Healthcare Venture Capital. The syndicate also incl... |
| 28.07.2021 | Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia | SHANGHAI, July 28, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluat... |
| 17.06.2021 | Eccogene : announces the addition of Jacques Mizrahi, PhD to Scientific Advisory Board | SHANGHAI, June 17, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced today the addition of Jacques Mizrahi, Ph.D., to it... |
| 17.06.2021 | Eccogene announces the addition of Jacques Mizrahi, PhD to Scientific Advisory Board | SHANGHAI, June 17, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced today the addition of Jacques Mizrahi, Ph.D., to it... |
| - | Eccogene | “Eccogene” |